Lengyel Erzsébet, Baricza Károly, Somogyi András, Olajos Judit, Pápai Zsuzsanna, Gödény Mária, Németh György, Esik Olga
Országos Onkológiai Intézet, Budapest, Sugárterápiás Osztály.
Orv Hetil. 2002 Oct 13;143(41):2343-50.
In the period between 1993 and 2000, 20 patients with nasopharyngael cancer were re-irradiated for locally recurrent carcinomas. The median duration between primary treatment and recurrence was 30 months. Brachytherapy was the method most frequently used in 10 cases alone, and in 8 cases in combination with external beam therapy. 2 patients underwent only external beam therapy. The external irradiation was performed with CT/MRI-based treatment planning. Brachytherapy involved a high dose rate afterloading method. The cumulative dose of re-irradiation was 20-60 Gy.
After a median follow-up of 37 months the overall survival and the local control were 60% (12/20) and 58% (7/12), respectively. 7 of the 12 surviving patients are currently tumour-free. After primary irradiation xerostomy occurred in all patients as an unavoidable side-effect of the treatment. A severe (grade 3 or higher according to the Common Toxicity Criteria version 2.0) late-side effect has so far been observed in 2 cases (10%). Authors' results lie in the medial range of the data in the international literature, though the rate of radiogen side-effects in the patient group is low. Both results are assumed to be a consequence of the re-irradiation dose being lower than the value considered optimum in the recent literature.
Re-irradiation of locally recurrent nasopharyngeal cancers is an efficient treatment modality, which should be used as a combination of external beam therapy and brachytherapy. The optimum cumulative dose is about 50-60 Gy. This dose results in a 5 years survival rate of about 40% with an acceptable (30%) risk. The results of re-irradiation may be improved, if PET is used to determine the extent of the surviving tumour tissue. This can help in the choice of the proper treatment modality.
在1993年至2000年期间,20例鼻咽癌患者因局部复发性癌接受了再程放疗。初次治疗与复发之间的中位时间为30个月。近距离放射治疗是最常用的方法,单独使用10例,8例与外照射联合使用。2例仅接受外照射。外照射采用基于CT/MRI的治疗计划。近距离放射治疗采用高剂量率后装技术。再程放疗的累积剂量为20 - 60 Gy。
中位随访37个月后,总生存率和局部控制率分别为60%(12/20)和58%(7/12)。12例存活患者中有7例目前无肿瘤。初次放疗后,所有患者均出现口干,这是治疗不可避免的副作用。到目前为止,2例(10%)出现严重(根据2.0版常见毒性标准为3级或更高)晚期副作用。作者的结果处于国际文献数据的中等范围,尽管患者组中放射性副作用的发生率较低。这两个结果都被认为是再程放疗剂量低于近期文献中认为最佳值的结果。
局部复发性鼻咽癌的再程放疗是一种有效的治疗方式,应将外照射和近距离放射治疗联合使用。最佳累积剂量约为50 - 60 Gy。该剂量可使5年生存率约为40%,风险可接受(30%)。如果使用PET来确定存活肿瘤组织的范围,再程放疗的结果可能会得到改善。这有助于选择合适的治疗方式。